Your browser doesn't support javascript.
Neurological comorbidities and COVID-19-related case fatality: A cohort study.
Romagnolo, Alberto; Imbalzano, Gabriele; Artusi, Carlo Alberto; Balestrino, Roberta; Ledda, Claudia; De Rosa, Francesco Giuseppe; Riccardini, Franco; Montanaro, Elisa; Bozzali, Marco; Rizzone, Mario Giorgio; Zibetti, Maurizio; Lopiano, Leonardo.
  • Romagnolo A; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy. Electronic address: alberto.romagnolo@unito.it.
  • Imbalzano G; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
  • Artusi CA; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
  • Balestrino R; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
  • Ledda C; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
  • De Rosa FG; SC Malattie Infettive U, AOU Città della Salute e Scienza, Turin, Italy; Department of Medical Sciences, University of Turin, Turin, Italy.
  • Riccardini F; Front Line P.S. P.O. Molinette, AOU Città della Salute e della Scienza, Turin, Italy.
  • Montanaro E; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
  • Bozzali M; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; Department of Neuroscience, Brighton & Sussex Medical School, University of Sussex, Brighton, East Sussex, United Kingdom.
  • Rizzone MG; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
  • Zibetti M; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
  • Lopiano L; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
J Neurol Sci ; 428: 117610, 2021 09 15.
Article in English | MEDLINE | ID: covidwho-1340734
ABSTRACT

BACKGROUND:

Neurological involvement in Coronavirus disease-2019 (COVID-19) is widely recognized. However, the role of pre-existing neurological comorbidities in modulating COVID-19-related mortality still remains unclear. This cohort study evaluates the COVID-19-related case fatality rate (CFR) of patients with pre-existing neurological diseases.

METHODS:

We retrospectively evaluated all patients consecutively admitted to our hospital with a diagnosis of COVID-19 between March and April 2020. We used a multivariate regression analysis to estimate the association between pre-existing neurological diseases and COVID-19-related mortality. Then, we compared the CFR and survival curves of two cohorts (patients suffering vs. those not suffering from pre-existing neurological disease), matched trough the propensity score (PS). Age and other comorbidities were considered for PS calculation. We applied a 11 matching for the entire neurological cohort and, separately, for cerebrovascular, neurodegenerative, and other neurological diseases.

RESULTS:

Among 332 patients, 75 (22.6%) were affected by pre-existing neurological disease (n = 29 cerebrovascular, n = 26 neurodegenerative, n = 20 others). From the multivariate regression analysis, they resulted with a significant increase of COVID-19-related mortality (OR2.559; 95%CI 1.181-5.545; p < 0.017). From the cohort analysis, CFR resulted 2-fold higher in patients with neurological disease (48.0% vs. 24.0%; p = 0.002). CFR was significantly higher in patients with neurodegenerative diseases compared to matched individuals (73.9% vs. 39.1%; p = 0.017), while CFR increase in patients with cerebrovascular diseases did not reach statistical significance (48.3% vs. 41.4%; p = 0.597).

CONCLUSIONS:

Pre-existing neurological comorbidities, in particular neurodegenerative diseases, increase significantly COVID-19-related case fatality, indicating a clear priority for viral screening, access to care facilities and vaccination in these populations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Neurol Sci Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Neurol Sci Year: 2021 Document Type: Article